| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| RAPT Therapeutics Inc. | Zelnecirnon (RPT193) | Atopic dermatitis | Phase 2b | Trial Discontinued | Oral | Immunology |
| RAPT Therapeutics Inc. | Ozureprubart (RPT904) | Asthma | Phase 2 | Ongoing | Intravenous | Respiratory |
| RAPT Therapeutics Inc. | RPT904 | Chronic spontaneous urticaria (CSU) | Phase 2 | Ongoing | oral | Immunology |
| RAPT Therapeutics Inc. | tivumecirnon (FLX475) in combination with pembrolizumab | Advanced Cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Recursion Pharmaceuticals Inc. | REC-2282 - (POPLAR-NF2) | Neurofibromatosis Type 2 | Phase 2/3 | Trial Discontinued | oral | Genetic Disorder |
| Recursion Pharmaceuticals Inc. | REC-394 | C. difficile | Phase 2 | Ongoing | Oral | Antibiotic |
| Recursion Pharmaceuticals Inc. | REC-3964 | Difficile Colitis | Phase 2 | Ongoing | Oral | Gastroenterology |
| Recursion Pharmaceuticals Inc. | REC-3599 | GM2 Gangliosidosis | Phase 2 | Ongoing | Intravenous | Genetic Disorder |